Ninsipapogene Sibarnarepvec is a recombinant vector vaccine commercialized by Hookipa Pharma, with a leading Phase II program in Oropharyngeal Cancer. According to Globaldata, it is involved in 2 clinical trials, which are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of Ninsipapogene Sibarnarepvec’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

Smarter leaders trust GlobalData

The revenue for Ninsipapogene Sibarnarepvec is expected to reach an annual total of $25 mn by 2039 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Ninsipapogene Sibarnarepvec Overview

Ninsipapogene sibarnarepvec (HB-202) is under development for the treatment of human papillomavirus (HPV) associated head and neck cancer squamous cell carcinoma, squamous cell carcinoma and oropharyngeal cancer. It is administered through intravenous route. The therapeutic candidate is a vaccine developed based on TheraT platform technology. The drug candidate acts by targeting human papillomavirus protein E6 and E7. It was under development for the treatment of anal cancer, vulvar cancer, penile cancer, cervical cancer and vaginal cancer.

Hookipa Pharma Overview

Hookipa Pharma (Hookipa) is a clinical-stage biopharmaceutical company that develops novel immunotherapies through its arenavirus platform for cancer and chronic infectious diseases using its replicating technology and non-replicating technology. Its pipeline products include HB-200 for the treatment of human papillomavirus 16-positive (HPV16+) cancers; HB-700 for the treatment of Kristen rat sarcoma viral oncogene homolog (KRAS) mutated cancers; HB-300 for the treatment of prostate cancer; HB-400 for hepatitis B (HBV) treatment; and HB-500 for the human immunodeficiency virus (HIV) treatment. Hookipa works in collaboration with other pharmaceutical companies for the development of immunotherapies. Hookipa is headquartered in New York, the US.

For a complete picture of Ninsipapogene Sibarnarepvec’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.